
Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …

The US FDA has approved AstraZeneca’s Zurampic to treat high levels of uric acid in the blood. The drug is …

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL). In the …

Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …

GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …

Janssen has announced a new collaboration and license agreement with Bavarian Nordic to develop a vaccine for chronic Human Papillomavirus …

Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …

Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …

Shire is set to sweeten its $30 billion bid for Baxalta by offering 40% of the total, or $12 billion, …

Drug safety regulators in Europe have said they will add warnings to the label and prescribing information of Gilenya (fingolimod), …

A new financial agreement announced this week as part of the Pharmaceutical Price Regulation Scheme (PPRS), will see the pharmaceutical …

Sun Pharma shares fell some 7% early this week after it emerged the Indian company received a warning letter from …

Michael Bonney, current board member and former chief executive of Cubist Pharmaceuticals, has been appointed as chairman of Alnylam Pharmaceuticals …

“We have a mission to encourage the pharmaceutical industry in improving access to medicine for the two billion people who …

Sir Kent Woods will step down as chair of the board at the EMA from the end of December 2015. …

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
Novartis has completed the acquisition of all outstanding rights to Arzerra from GSK for up to $1.034 billion. The deal, …

The year 2016 is set to see continued growth in research and development productivity, with significant new drug launches and …

After months of discussion, ISIS Pharmaceuticals has changed its name to Ionis to free itself from the fear of confusion …

When Merck unveiled its Africa 2020 strategy in November, there was no shortage of ambition.The company announced plans to expand …